health
Preclinical study links neutrophil interferon signalling to anti-PD-1 resistance
A bioRxiv preprint reports that an early interferon-responsive neutrophil program tracked resistance to anti-PD-1 therapy in preclinical models of triple-negative breast cancer. Genetic disruption of interferon signalling in neutrophils improved treatment responses in those models.